Destiny Pharma Sees Potential For XF-73 In Oral Mucositis
Added Indication For Phase III-Ready Asset
A new research program exploring an additional indication for XF-73 will help the UK biotech's licensing discussions for the nasal gel.
You may also be interested in...
The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.